Value202020212022202320242025TTMSelling/general/admin expenses6.71 M21.23 M32.55 M33.3 M26.09 M16.68 M16.68 MResearch & development13.29 M42.79 M61.46 M93.79 M70.68 M17.5 M17.5 MOperating income-20 M-64.02 M-104.02 M-125.47 M-100.9 M-102.27 M-102.27 MNon-Operating Income, Total-1.28 M334 K3.22 M7.64 M3.96 M1.24 M1.24 MInterest expense, net of interest capitalized367 K3 000—————Non-Operating Income, excl. Interest Expenses-367 K-3 00000000Unusual income/expense-1.28 M334 K3.22 M7.64 M3.96 M1.24 M1.24 MPretax income-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-128.33 MEquity in earnings———————Taxes-4.3 M-13.5 M-20.4 M-28.3 M-20.7 M0—Non-controlling/minority interest———————After tax other income/expense———————Net income before discontinued operations-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-105.61 MDiscontinued operations———————Net income-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-105.61 MDilution adjustment———————Preferred dividends———————Diluted net income available to common stockholders-19.95 M-54.85 M-95.64 M-117.67 M-96.94 M-105.61 M-105.61 MBasic earnings per share (Basic EPS)——-25.3-30.9-25.2-24.7-24.7Diluted earnings per share (Diluted EPS)——-25.3-30.9-25.2-24.7-24.7Average basic shares outstanding——3.77 M3.8 M3.85 M4.28 M16.03 MDiluted shares outstanding——3.77 M3.8 M3.85 M4.28 M16.03 MEBITDA-19.54 M———-100.45 M——EBIT-19.8 M———-100.91 M——Cost of revenue———————Other cost of goods sold———————Depreciation & amortization (cash flow)253 K972 K423 K-445 K455 K643 K643 K
LeonaBio Inc
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer.